Tisagenlecleucel Nears European Approval for DLBCL, ALL
Pharma & biotech2018-06-29
15 Views
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of tisagenlecleucel for the treatment of either adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
The Best Web Architectures for Your Business App
Moderna (Nasdaq: MRNA) Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273)
